Scientech Research LLC Has $203,000 Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Scientech Research LLC reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 69.4% during the second quarter, Holdings Channel reports. The institutional investor owned 492 shares of the company’s stock after selling 1,114 shares during the period. Scientech Research LLC’s holdings in Medpace were worth $203,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MEDP. Rise Advisors LLC purchased a new stake in shares of Medpace during the 1st quarter worth approximately $27,000. Mather Group LLC. purchased a new stake in Medpace in the first quarter worth $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Medpace in the first quarter valued at $31,000. DT Investment Partners LLC purchased a new position in shares of Medpace during the 2nd quarter valued at $41,000. Finally, J.Safra Asset Management Corp grew its stake in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after acquiring an additional 47 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP stock opened at $333.45 on Wednesday. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The business’s fifty day moving average is $366.33 and its 200 day moving average is $388.94. The company has a market capitalization of $10.33 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 1.88 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter last year, the company posted $1.93 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MEDP shares. TD Cowen lowered their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Finally, Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and lowered their price target for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $395.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.